微创介入治疗肝癌对机体免疫功能影响的研究现状与展望

doi:10.3969/j.issn.1672-5069.2014.03.003

摘要/Abstract

Key words: Hepatocellular carcinoma, Immune function, Ablation

张跃伟. 微创介入治疗肝癌对机体免疫功能影响的研究现状与展望[J]. 实用肝脏病杂志, 2014, 17(3): 231-234.

Zhang Yuewei. Effect of local ablative therapy on host immune function in patients with hepatocellular carcinoma: present status and prospective[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(3): 231-234.

参考文献

[1] Imamura H,Matsuyama Y,Tanaka E,et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol,2003,38（2）:200-207.
[2] Mizukoshi E,Nakamoto Y,Arai K,et al.Comparative analysis of various. Hepatology,2011,53（4）:1206-1216.
[3] Fu J,Xu D,Liu Z,et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology,2007,132（7）:2328-2339.
[4] Gao Q,Qiu SJ,Fan J,et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol,2007,25（18）:2586-2593.
[5] Chang MH,Chen CJ,Lai MS,et al.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma,Study Group. N Engl J Med,1997,336（26）:1855-1859.
[6] Park EJ,Lee JH,Yu GY,et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell,2010,140（2）:197-208.
[7] Tarley BQ,Calcagno CJ,Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma:a weighty connection. Hepatology,2010,51（5）:1820-1832.
[8] Mizukoshi E,Nakamoto Y,Arai K,et al.Comparative analysis of various tumor-associated antigen-specific T cell responses in patients with hepatocellular carcinoma. Hepatology,2011,53（4）:1206-1216.
[9] Korangy F,Ormandy LA,Bleck JS,et al. Spontaneous tumor-specific humoral and cellular immuneresponses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Re,2004,10（13）:4332-4341.
[10] Hoechst B,Voigtlaender T,Ormandy L,et al. Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology,2009,50（3）:799-807.
[11] Pinato DJ,Stebbing J,Ishizuka M,et al. A novel and validated prognostic index in hepatocellular carcinoma:The inflammation based index （IBI）. J Hepatol,2012,57（5）:1013-1020.
[12] Ishizuka M,Kubota K,Kita J,et al. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma:a retrospective study of 398 Japanese patients. Am J Surg,2012,203（1）:101-106.
[13] Fu J,Xu D,Liu Z,et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology,2007,132（7）:2328-2339.
[14] Arihara F,Mizukoshi E,Kitahara M,et al.Increase in CD14（t）HLA-DR （-/low） myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol Immunother,2013,62（8）:1421-1430.
[15] 张志刚,张跃伟. 肝癌微创治疗对机体T淋巴细胞亚群影响的研究现状. 中华肿瘤防治杂志,2012,19（12）：609-612.
[16] Xiong B,Feng G,Luo S,et al. Changes of CD4 + CD25 + regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE. J Huazhong Univ Sci Technolog Med Sci,2008,28（6）:645-648.
[17] Nobuoka D,Motomura Y,Shirakawa H,et al. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes. Int J Oncol,2012,40（1）:63-70.
[18] Ayaru L,Pereira SP,Alisa A,et al.Unmasking of alpha-fetoprotein-specific CD4（t） T cell responses in hepatocellular carcinoma patients undergoing embolization. J Immunol,2007,178（3）:1914-1922.
[19] Hiroishi K, Eguchi J,Baba T,et al. StrongCD8（t） T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol,2010,45（4）:451-458.
[20] 李刚,寸英丽,杨丽春. 肝癌患者射频消融后血清Th1、Th2型细胞因子的变化. 肝胆胰外科杂志,2010,22（2）：94-96.
[21] Zerbini A,Pilli M,Fagnoni F,et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J. Immunother,2008,31（3）:271-282.
[22] Hansler J,Wissniowski TT,Schuppan D,et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. World J Gastroenterol,2006,12（23）:3716-3721.
[23] Mizukoshi E,Yamashita T,Arai K et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma.Hepatology,2013,57（4）:1448-1457.
[24] Zerbini A,Pilli M,Laccabue D,et al. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response. Gastroenterology,2010,138（5）:1931-1942.
[25] Osada S,Imai H,Tomita H,et al. Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol,2007,95（6）:491-498.
[26] Zeng Z,Shi F,Zhou L,et al. Upregulation of circulating PD-L1/PD-1 is associated with poor postcryoablation prognosis in patients with HBV-related hepatocellular.carcinoma. PLoS One,2011,6（9）:e23621.
[27] den Brok MH,Sutmuller RP,Nierkens S,et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity.Br J Cancer,2006,95（7）:896-905.
[28] Wu F,Wang ZB,Lu P,et al. Activated antitumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol,2004,30（9）:1217-1222.
[29] Xia JZ,Xie FL,Ran LF,et al. High-intensity focused ultrasound tumor ablation activates autologous tumor-specific cytotoxic T lymphocytes. Ultrasound Med Biol,2012,38（8）:1363-1371.